Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Stefan Lorenz

Stefan Dengl

Joerg Moelleken

Johannes Auer

Martin Bader

Stefan Seeber

Hubert Kettenberger

Olaf Mundigl

Sabine Imhof-Jung

Guido Hartmann

Jens Fischer

Kristian Hobolt Jensen

Joerg Benz

Roland Beckmann

Peter Michael Huelsmann

Christian Gassner

Maximiliane Koenig

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Antibody that binds to VEGF and IL-1beta and methods of use

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B-CS-I-CS-FC-CS-I-CS-B), wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.

Method for producing monomeric and multimeric molecules and uses thereof

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B-CS-I-CS-FC-CS-ICS-B), wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.

Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.

TNFa-IL-17 bispecific antibodies

The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies against human TWEAK and human IL17 and uses thereof

Growing community of inventors

Penzberg, Germany

Stefan Lorenz